ArticleCancer medicine2025
Optimizing Deep Learning Models for Luminal and Nonluminal Breast Cancer Classification Using Multidimensional ROI in DCE-MRI-A Multicenter Study.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Optimizing Deep Learning for Renal Mass Characterization in Challenging Cases: A Comparative Study of Spatial-Input Strategies and a Validated ROI-Only DLR Nomogram.Annals of surgical oncology · 2026Article
- ASO Author Reflections: From Four Spatial-Input Strategies to a Full Exhaustive Paradigm-Refining Deep Learning Radiomics for Challenging Renal Masses.Annals of surgical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesPrevious deep learning studies have not explored the synergistic effects of ROI dimensions (2D/2.5D/3D), peritumoral expansion levels (0-8 mm), and segmentation scenarios (ROI only vs. ROI original). Our study aims to evaluate the performance of multidimensional deep transfer learning models in distinguishing molecular subtypes of breast cancer (luminal vs. nonluminal) using DCE-MRI. Under two segmentation scenarios, we systematically compare the effects of ROI dimensions and peritumoral expansion levels to optimize multidimensional deep learning models via transfer learning for distinguishing luminal from nonluminal breast cancers in DCE-MRI-based analysis. MATERIALS AND
methodsFrom October 2020 to October 2023, data from 426 patients with primary invasive breast cancer were retrospectively collected. Patients were divided into three cohorts: (1) training cohort, n = 108, from SYSU Hospital (Zhuhai, China); (2) validation cohort 1, n = 165, from HZ Hospital (Huizhou, China); and (3) validation cohort 2, n = 153, from LY Hospital (Linyi, China). ROIs were delineated, and expansions of 2, 4, 6, and 8 mm beyond the lesion boundary were performed. We assessed the performance of various deep transfer learning models, considering precise segmentation (ROI only and ROI original) and varying peritumoral regions, using ROC curves and decision curve analysis.
resultsThe 2.5D1-based deep learning model (ROI original, 4 mm expansion) demonstrated optimal performance, achieving an AUC of 0.808 (95% CI 0.715-0.901) in the training cohort, 0.766 (95% CI 0.682-0.850) in validation cohort 1, and 0.799 (95% CI 0.725-0.874) in validation cohort 2.
conclusionThe study highlights that the 2.5D1-based deep learning model utilizing the three principal slices of the minimum bounding box (ROI original) with a 4 mm peritumoral region is effective in distinguishing between luminal and nonluminal breast cancer tumors, serving as a potential diagnostic tool.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.